Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis
December 1st 2006This report describes the Food and Drug Administration's review of data and analyses leading to the approval of the oral iron chelator, deferasirox for the treatment of chronic iron overload due to transfusional hemosiderosis.